申请人:Max-Planck-Gesellschaft zur Förderung
der Wissenschaften e.V.
公开号:EP2818471A1
公开(公告)日:2014-12-31
The present invention relates to compounds assumed to be capable of modulating the activity of the proteins ScyI1 and Grk5, thereby regulating the expression and/or release of insulin as well as to pharmaceutical compositions containing such compounds and the use thereof especially for the treatment of a metabolic disease such as diabetes, obesity and impaired adipogenesis.
本发明涉及假设能够调节蛋白质ScyI1和Grk5活性的化合物,从而调节胰岛素的表达和/或释放,以及包含此类化合物的药物组合物及其用途,特别是用于治疗糖尿病、肥胖和脂肪生成受损等代谢性疾病。